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Objectives. This work aims to evaluate the association between antigen carbohydrate 125 
(CA125) and the risk of 1-year clinical outcomes in patients with worsening heart failure 
(HF).  
Background. CA125 is a widely available biomarker that is up-regulated in patients with 
acute HF and has been postulated as a useful marker of congestion and risk stratification.  
Methods. In a large multicenter cohort of patients with worsening HF, either in-hospital or in 
the outpatient setting, the independent associations between CA125 and 1-year death and the 
composite of death/HF-readmission (adjusted for BIOSTAT risk score) were determined with 
the Royston-Parmar method (n=2356). In a sensitivity analysis, the prognostic implications of 
CA125 were also adjusted for a clinical congestion score (CCS). Data were validated in the 
BIOSTAT-CHF validation cohort (n=1630). 
Results. Surrogates of congestion, such as NT-proBNP and a CCS, emerged as independent 
predictors of CA125. In multivariable survival analyses, higher CA125 was associated with 
an increased risk of mortality and the composite of death/HF-readmission (p<0.001 for both 
comparisons), even after adjustment for the CCS (p<0.010 for both comparisons). The 
addition of CA125 to the BIOSTAT score led to a significant risk reclassification for both 
outcomes (category-free net reclassification improvement=0.137, p<0.001 and 0.104, 
p=0.003, respectively). All outcomes were confirmed in an independent validation cohort.  
Conclusions. In patients with worsening HF, higher levels of CA125 were positively 
associated with parameters of congestion. Furthermore, CA125 remained independently 
associated with a higher risk of clinical outcomes, even beyond a predefined risk model and 
clinical surrogates of congestion. 





We aimed to evaluate the association between carbohydrate antigen 125 (CA125) (postulated 
as a marker of congestion) and the risk of 1-year clinical outcomes (death and the composite 
of death/HF-readmission) in 2356 patients with worsening heart failure (HF). Data were 
validated in the BIOSTAT-CHF validation cohort (n=1630). Surrogates of congestion 
emerged as independent predictors of CA125. In multivariable survival analyses, higher 
levels of CA125 were associated with an increased risk of clinical events (p<0.001 for both 
comparisons), even beyond a predefined risk model and clinical surrogates of congestion. All 
outcomes were confirmed in an independent validation cohort.  
 
ABBREVIATIONS 
AHF: Acute Heart Failure 
BIOSTAT-CHF: A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure 
CA125: Carbohydrate Antigen 125 
eGFR: Estimated Glomerular Filtration Rate 
FO: Fluid Overload 
HF: Heart Failure 
LVEF: Left Ventricular Ejection Fraction 









Congestion plays a major role in the pathogenesis of acute heart failure (AHF) 
syndromes; however, its severity and organ distribution are largely heterogeneous (1,2). Due 
to the limited accuracy of routine clinical assessment for identifying and monitoring systemic 
congestion (1,2), there is a growing interest in searching for a reliable marker for congestion. 
For instance, recent evidence shows that the biologically active form of adrenomedullin (Bio-
ADM) is positively associated with symptoms and signs of congestion and a higher risk of 
adverse outcomes in patients with worsening heart failure (HF) (3). Along this same line, 
plasma carbohydrate antigen 125 (CA125) has also emerged as a potential biomarker of 
congestion in this same setting (4,5). In fact, plasma levels of this glycoprotein are elevated in 
up to 60-70% of patients with AHF, and higher levels were correlated to congestion severity 
and adverse prognosis (4,5). Interestingly, this biomarker has also shown promising 
properties for monitoring the clinical course and guiding therapy following an episode of 
AHF (4-6). For instance, in a recent clinical trial of 380 patients with a recent episode of 
AHF, CA125-guided therapy was associated with a reduction of 1-year death/AHF-related 
risk (7). This effect was attributed to a better individualization of patients’ decongestive 
therapy. Despite this evidence, the pathophysiology and clinical role of this glycoprotein in 
AHF management is not well established. Moreover, its prognostic ability for predicting 
clinical outcomes must be confirmed, particularly in settings where traditional 
prognosticators and clinical surrogates of congestion are included. 
In the present work, we aimed to: a) evaluate the independent association between 
CA125 and the risk of 1-year clinical outcomes (death/AHF-readmission), b) determine 
whether the prognostic value of this biomarker remains significant after adjusting for clinical 
proxies of congestion, and c) relate its values with other HF-biomarkers and clinical 





BIOSTAT-CHF Cohort (Derivation cohort) 
The BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-
CHF) was a multicentre, multinational, prospective, observational study that included 2516 
patients with worsening signs and/or symptoms of HF from 69 centers in 11 European 
countries (8).  The recruitment period was 24 months, from December 2010 to December 
2012. Median follow-up was 21 months [interquartile range (IQR) 15–27 months]. Patients 
were included after presentation with either new onset or worsening HF, which was defined 
as left ventricular ejection fraction (LVEF)≤40% and/or brain natriuretic peptide (BNP)>400 
pg/mL or N-terminal pro-brain natriuretic peptide (NT-proBNP)>2000 pg/mL. Patients were 
expected and encouraged to be up-titrated to recommended treatment doses. All patients 
enrolled in BIOSTAT-CHF provided written informed consent to participate in the study and 
BIOSTAT-CHF was conducted in concordance with the declaration of Helsinki, national 
ethics,and legal requirements, as well as relevant EU legislation. The study was also 
approved by national and local ethics committees. The characteristics of the BIOSTAT-CHF 
cohort have been described elsewhere (8). In brief, most patients were hospitalized for AHF, 
and the remainder presented with worsening signs and/or symptoms of HF at outpatient 
clinics.  
All deaths and hospitalizations were recorded. The primary outcome of interest was 
time to a composite of death or unscheduled hospitalization for HF. The co-primary endpoint 
was time to all-cause mortality. The secondary endpoint was to identify the clinical 
determinants of CA125. 
 
Validation cohort  
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Data were validated in the BIOSTAT-CHF validation cohort consisting of 1738 HF 
patients from six centers in Scotland, UK, which has also been described in detail before (9). 
In summary, patients≥18 years old diagnosed with HF with a previous hospital admission for 
HF requiring diuretic treatment and current treatment with furosemide≥20 mg/day or 
equivalent were included. They had previously not been treated or received≤50% of target 
doses of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers 
(ARB) and/or beta-blockers. 
  
Congestion assessment 
A composite congestion score (CCS) was calculated for individual patients at baseline 
using a modified and validated algorithm as described by Ambrosy et al. (10,11). The CCS 
was calculated by summing the individual scores for orthopnea, peripheral edema, and 
jugular venous distension. The presence of orthopnea and jugular venous distension 
contributed to the CCS with 1 point each one.  However, peripheral edema used different 
weights to match its severity: the absence of edema, 0; edema limited to the ankles, 0.33; 
edema below the knees, 0.66; and edema above the knees, 1. By summing integer and non-
integer scores, the final CCS was treated in the analysis as a continuous variable. Just for a 
sensitivity analysis, the CCS was categorized in: no congestion (CCS=0), mild congestion 
(CCS=1 or 2), and severe congestion (CCS≥3), by reclassifying edema into two categories: 
0=no edema, edema limited to ankles, and edema below the knees, and 1=edema above the 
knees (11). Categorical CCS is referred heretofore as CCS_3C. Additionally, the presence of 
hepatomegaly and pulmonary rales >1/3 up lung fields were assessed. 
 
 CA125 measurement 
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CA125 was measured using the ARCHITECT CA 125 II assay (lot.81007M800), a 
chemiluminescent microparticle immunoassay (CMIA), on the ARCHITECTi System 
(Abbott Laboratories). The specificity and the precision of the ARCHITECT CA 125 II assay 
were ≤12% and 10% total CV, respectively. The sensitivity of the assay was ≤1.0 U/mL. 
Analytical sensitivity corresponds to the upper limit of the 95% confidence interval and 
represents the lowest concentration that can be distinguished from zero. The normal range of 
CA125 established for this assay is 35 U/mL. CA125 was measured from frozen samples. 
Clinical endpoint adjudications were blinded to CA125 status. NT-proBNP was measured 
using electrochemiluminescence on a Cobas e411 analyzer, using standard methods (Roche 
Diagnostics GmbH, Mannheim, Germany). 
A great number of other biomarkers from multiple pathophysiological domains, 
including markers of inflammation, apoptosis, remodeling, myocyte stress, angiogenesis, 
endothelial function, and renal function were also measured (Online file 1). 
 
Statistical analysis 
Baseline characteristics among CA125 quartiles (CA125-Q4) were compared by 
either ANOVA, Kruskall–Wallis, or chi-squared tests, as appropriate. 
 
Correlation heatmap and dendrogram 
Spearman correlation was determined between CA125 and age, systolic blood 
pressure, urea, estimated glomerular filtration rate (eGFR), serum sodium, serum potassium, 
NT-proBNP, NYHA class, CCS, Bio-ADM, growth differentiation factor-15 (GDF-15), IL-6, 
ET-1, PENK, renin, and aldosterone. Because of listwise deletion, the final sample in which 
the correlation analysis was based included 978 patients. The same sets of variables were 
included in hierarchical cluster analysis (agglomerative type) with ward.D2 linkage method, 
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and Spearman correlation matrix as a dissimilarity measure. No significant differences were 
found in those included vs. excluded (Online file 2).  
 
Association between congestion and CA125 
With log-transformed CA125 as the dependent variable, the following covariates were 
included in the final linear regression model: CCS, age, systolic blood pressure, serum 
sodium, NT-proBNP, heart rate, pulmonary rales/crackles, and hepatomegaly. The added 
value of each covariate on model’s R2 was used as an indicator of predictor’s importance.  
 
CA125 as a clinical outcome predictor 
By means of a flexible parametric regression modeling –Royston-Parmar model– we 
determined the independent prognostic effect of CA125 on both clinical outcomes. Estimates 
of risk were adjusted for the outcome-specific prognostic risk score (BIOSTAT-risk score 
(9). The BIOSTAT risk score for mortality included age, blood urea nitrogen, NT-proBNP, 
serum hemoglobin, and the use of a beta-blocker. The BIOSTAT risk score for the composite 
endpoint included age, previous HF-hospitalization, peripheral edema, systolic blood 
pressure, NT-proBNP, hemoglobin, high-density lipoprotein, sodium, and use of beta-
blocker. 
The linearity assumption for CA125 and the prognostic risk score was tested with 
multivariable fractional polynomials (FP) (12). Risk estimates from the Royston-Parmar 
model are presented as hazard ratios (HR) with 95% CIs. Harrell C-statistics was used as the 
metric for the model’s performance. In a sensitivity analysis, the CCS, together with 
BIOSTAT-risk score, was also included in the prognostic models (n=1426) to evaluate how 
much of its effect is mediated by clinical surrogates of congestion. The added value of 
CA125 on models’ discriminative ability was estimated with changes in C-statistics, the 
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integrated discrimination improvement (IDI), and category-free net reclassification 
improvement (cfNRI). 
We set a two-sided p-value of <0.05 as the threshold for statistical significance. Stata 
15.1 (Stata Statistical Software, Release 15 [2017]; StataCorp LP, College Station, TX, 
USA), was used for the main analysis. Risk reclassification analyses (survIDINRI and 
SurvC1 modules) and dendrogram were implemented in R (Version 3.5.2; R Foundation for 
Statistical Computing, Vienna, Austria). A more detailed description of statistical analyses is 





A total of 2356 from 2516 patients included in the BIOSTAT-CHF cohort were 
included in this analysis. The mean age of the sample was 69±12 years; 614 (26.1%) were 
female, 1287 (55.6%) had a history of ischemic heart disease, and 1884 (89.3%) had an 
LVEF ≤40%. Median (IQR) of CA125 and NT-proBNP were 38.6 U/ml (16-125), and 2699 
pg/mL (1179-5764), respectively. Baseline characteristics across quartiles of CA125 are 
shown in table 1. Overall, higher values of CA125 were found in older patients, those with 
higher rates of atrial fibrillation, worse prior NYHA class, and more severe AHF severity 
proxies (lower systolic and diastolic blood pressure, hemoglobin, and eGFR). Likewise, 
patients in the upper quartiles showed a worse echocardiographic profile (lower LVEF, 
higher left atrial diameter and a higher proportion of mitral valve regurgitation), and greater 
evidence of clinical congestion. Regarding the use of medications at baseline, lower rates of 
beta-blockers and ACEI/ARB were found in the upper quartiles (Table 1). 
In the validation cohort (n=1630 from 1738 patients of the validation cohort), the 
distribution of baseline characteristics among quartiles of CA125 showed an overall higher 
risk profile as CA125 values increases. Higher levels of CA125 were associated with a prior 
history of HF hospitalizations, higher NYHA class and heart rate, poor renal dysfunction, and 
higher NT-proBNP. An inverse association was found between CA125 and age, systolic 
blood pressure, hemoglobin, sodium, and potassium (Online file 3). 
 
Heatmap and dendrogram 
Figure 1a shows the Spearman correlation heatmap coefficients. CA125 had the 
strongest correlation with NT-proBNP (rho=0.42, p<0.001), followed by GDF-15 (rho=0.40, 
p<0.001), ET-1 (rho=0.38, p<0.001), IL-6 (rho=0.35, p<0.001), Bio-ADM (rho=0.35, 
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p<0.001), the CCS (rho=0.34, p<0.001), NYHA class (rho=0.26, p<0.001), heart rate 
(rho=0.23, p<0.001), and serum sodium (rho=-0.15, p<0.001).  
In a hierarchical cluster analysis (Figure 1b), CA125 clustered with the combined 
effect of Bio-ADM, ET-1, IL-6, NT-proBNP, and GDF-15, which, in turn, clustered together 
with the combined effect of NYHA class, and the CCS. 
Similar findings were obtained in the validation cohort (Online file 4). CA125 
correlated with NT-proBNP (rho=0.52, p<0.001), GDF-15 (rho=0.37, p<0.001), Bio-ADM 
(rho=0.30, p<0.001), NYHA class (rho=0.24, p<0.001), PENK (rho=0.20, p<0.001) heart rate 
(rho=0.20, p<0.001), serum potassium (rho=-0.16, p<0.001), systolic blood pressure  (rho=-
0.15, p<0.001) , urea (rho=0.15, p<0.001), eGFR (rho=-0.13, p<0.001), and serum sodium 
(rho=-0.13, p<0.001). The dendogram showed that CA125 clustered with NT-proBNP. Both 
clustered together with the combined effect of NYHA class, Bio-ADM, and GDF-15 (Online 
file 5). 
 
CA125 as marker of congestion 
The analysis showed that the most important predictors of log transformed CA125 
(line-up based on the magnitude of its contribution to the total R2 of the model) were: 1) NT-
proBNP [∆R2=0.184; p<0.001], CCS [∆R2=0.040; p<0.001], age [∆R2=0.020; p<0.001], 
serum sodium [∆R2=0.015; p<0.001], heart rate [∆R2=0.006; p=0.001], pulmonary 
rales/crackles [∆R2=0.006; p=0.004], systolic blood pressure [∆R2=0.003; p=0.027], and 
hepatomegaly [∆R2=0.0008; p=0.226]. The full model R2 was 0.277. Detailed model is 
shown in Table 2. The contribution of adding the block of all congestion-related variables 
(NT-proBNP, CCS, serum sodium, pulmonary rales/crackles and hepatomegaly) to age, heart 
rate and systolic blood pressure represents a ∆R2=0.22; p<0.001, which is equivalent to 
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79.4% of the total model R2. Figure 2 shows the independent association between CCS and 
NT-proBNP with log transformed CA125. 
In the validation cohort, the independent variables associated with log transformed 
CA125 were, in order of importance: NT-proBNP [∆R2=0.256; p<0.001], serum potassium 
[∆R2=0.016; p<0.001], serum sodium [∆R2=0.015; p<0.001], heart rate [∆R2=0.014; 
p<0.001], systolic blood pressure [∆R2=0.005; p=0.004], age [∆R2=0.003; p=0.033], and 





During a 1-year follow-up, 369 deaths were registered. Unadjusted mortality rates 
(per 100 person-years) significantly differed across quartiles of CA125 (8.53, 12.17, 21.21, 
and 29.33 for Q1, Q2, Q3, and Q4, respectively; p<0.001). Kaplan-Meier curves are shown in 
online file 6. 
In a multivariable survival analysis that included the BIOSTAT risk score for 
mortality as a covariate, the continuum of CA125 revealed a positive, sigmoid-shaped 
association with the risk of mortality (C-statistics=0.757; overall p-value<0.001) (Figure 3a). 
The adjusted association between CA125 (log CA125 and quartiles) and mortality is 
presented in table 3.  
 
Composite of death and/or rehospitalization for AHF 
At a median follow-up of 1-year, 678 combined endpoints were ascertained. The rates 
(per 100 person-years) of this composite endpoint significantly differed among CA125 
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quartiles (18.6, 30.3, 41.7, and 56.6 for Q1, Q2, Q3, and Q4, respectively; p<0.001). Kaplan-
Meier curves are shown in online file 7. 
Multivariable analysis showed that CA125 was significantly associated with this 
endpoint, through a positive and also sigmoid-shaped curve (C-statistics=0.719; overall p-
value<0.001) (Figure 3b). Risk estimates (log CA125 and quartiles) for the composite 
endpoint are presented in table 3. In the derivation cohort, CA125 (log CA125 and quartiles) 
remained significantly associated with the risk of the combined endpoint (Table 3). 
 
Sensitivity analysis 
In a sensitivity analysis, where the CCS was added as an additional covariate 
(n=1426), the results were in line with the main findings (Figures 4a and 4b). Furthermore, 
we also found that the predictive ability for all-cause mortality of CA125 for both endpoints 
(here dichotomized at 35 U/mL) was consistent across all levels of the CCS_3C (Online files 
8 and 9). 
 
Survival model’s performance 
All-cause mortality. 
Online file 10 summarizes the survival model´s performance. The models that 
included CA125 showed a significant risk reclassification compared to BIOSTAT risk score 
(IDI=0.008, 95% CI: 0.001-0.020, p=0.010 and cfNRI=0.137, 95% CI: 0.073-0.184, 
p<0.001) or BIOSTAT risk score+NT-proBNP  (IDI=0.005, 95% CI: 0.001-0.013, p=0.043 
and cfNRI=0.106, 95% CI: 0.021-0.161, p=0.027). However, the ∆C statistic did not 
significantly differ when adding CA125 to BIOSTAT risk score (∆=0.004, CI:-0.001-0.010) 




Composite of death and/or rehospitalization for AHF 
The addition of CA125 led to a significant risk reclassification compared to 
BIOSTAT risk score (IDI=0.009, 95% CI: 0.003-0.017, p<0.001 and cfNRI=0.104, 95% CI: 
0.061-0.150, p=0.003) and borderline when compared to BIOSTAT risk score+NT-proBNP 
(IDI=0.004, 95% CI:0.001-0.010, p=0.040 and cfNRI=0.050, 95% CI:-0.013-0.086 p=0.106). 
The ∆C statistic was significantly higher when compared to BIOSTAT risk score (∆=0.006, 
95% CI: 0.001-0.010) but not when compared to BIOSTAT risk score+NT-proBNP 
(∆=0.002, CI: -0.001-0.005). 
 
Validation cohort 
In a univariate as well as in multivariable context, CA125 also demonstrated to be a 
significant and independent predictor for 1-year all-cause mortality and for the composite of 




The present study confirms the role of CA125 as a surrogate of congestion and its 
utility as a prognostic biomarker in worsening HF, confirming findings from previous smaller 
studies. In fact, the present data from a sub-analysis of the BIOSTAT-CHF and the validation 
cohorts indicate that CA125 was strongly associated with higher risk of 1-year all-cause 
mortality and the combined of all-cause death and hospitalization for HF. The merit of this 
study stems from a rigorous model’s adjustment including clinical surrogates of systemic 
congestion. Moreover, through a cluster analysis, CA125 grouped with recognized 
biomarkers of congestion and inflammation. Congruent results were also found in the 
validation cohort. 
 
CA125 as a marker of congestion 
Symptoms and signs of congestion are found in most patients with AHF; however, its 
presence and severity are largely heterogeneous (1,2). Unfortunately, traditional clinical 
assessment of congestion through symptoms and signs has shown a limited accuracy (1,2).  
Thus, current experts recommend an integrative multi-parameter-based evaluation of 
congestion using clinical assessment, biomarkers, and supplemented with technical 
assessments (1-3). Despite these recommendations, a well-validated tool for clinical 
assessment of congestion is still an unmet need. In the last years, CA125 has emerged as a 
novel useful biomarker of congestion (4,5). The pathophysiology of CA125 in AHF remains 
largely unknown. What is known is that this large glycoprotein is synthesized by mesothelial 
cells in response to an increase in hydrostatic pressures and/or inflammatory mediators (4,5). 
In patients with AHF, CA125 has shown to be related to symptoms or signs of fluid overload, 
such as peripheral edema, serosal effusion, pulmonary wedge pressure, and increasing cardiac 
pressures (4,5,13,14).  Consistent with this notion, a recent meta-analysis showed that 
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patients with significant serosal effusions had higher CA125 levels (15). However, in patients 
with refractory congestive HF treated with continuous peritoneal dialysis, CA125 decreased 
in parallel with decongestion and despite the peritoneal irritation induced by the presence of 
an osmotic solution into the peritoneum (16). These findings suggest that increases in CA125 
associated with serosal effusion are parallel processes caused by common pathophysiological 
mechanisms, and not necessarily a cause-effect phenomenon. Interestingly, in the present 
study, we found that CA125 was strongly associated with well-validated proxies of clinical 
congestion. In addition, their values were also positively related to biochemical surrogates of 
increased filling pressures/congestion such as NT-proBNP and Bio-ADM (3). In a recent 
analysis of 2179 patients with worsening HF, ter Maaten et al. reported Bio-ADM was related 
to symptoms and signs of congestion (3). Interestingly, in the cluster analysis CA125 and 
Bio-ADM grouped together. These findings suggest both biomarkers may play a crucial role 
in identifying the degree of congestion in patients with worsening HF.   
Future studies should investigate the exact role of CA125 in the identification of 
intravascular vs. extravascular congestion. In addition, a formal comparison with other novel 
biomarkers of congestion is still required. 
 
CA125 and risk stratification 
Prior studies have reported a significant association between CA125 and the risk of death and 
HF-readmission in different AHF scenarios (4-6,13-15,17). This is the largest study in AHF 
confirming the prognostic value of CA125 independent of standard prognosticators. 
Additionally, present findings also support that the value of these biomarkers for risk 
stratification is independent of traditional symptoms/signs of congestion. Interestingly, the 
association between CA125 and adverse clinical events remained significant in those with 
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mild, moderate, and severe congestion. Such behavior opens an avenue for its incorporation 
in multi-parametric congestion scores.  
 
CA125 assessment in AHF.  Ready for clinical implementation? 
In our opinion, the following aspects may contribute to endorsing the use of CA125 
into a routine clinical practice: a) the lack of standardized biomarkers for assessing 
congestion in daily clinical practice; b) wide availability and low cost (≈1€), c) independent 
predictive ability beyond clinical and biochemical markers of congestion (including 
natriuretic peptides) (4-6,17); d) longitudinal trajectories highly associated with risk of 
adverse outcomes (4-6), and; e) potential utility for guiding depletive therapy (7,18). 
Regarding, this last point, the CHANCE-HF trial, performed in 380 patients discharged for 
AHF and high CA125, CA125-guided therapy (up or down-titrating depletive treatment when 
CA125 increased or decreased during follow-up) was superior to the standard of care in terms 
of reducing the risk of the composite of 1-year death or AHF readmissions (7). More 
recently, a CA125-guided diuretic strategy (intensive diuretic therapy in patients with 
CA125>35 U/ml and more conservative approach when CA125≤35 U/ml) was evaluated in 
an open-label randomized study that enrolled 160 patients with AHF and renal dysfunction at 
presentation (mean eGFR of 33.7±11.3 mL/min/1.73m2) (18). In this trial, the CA125-guided 
strategy significantly improved eGFR and other renal function parameters at 72h (18). In 
summary, and beyond logistic issues, there is promising data supporting the clinical utility of 
CA125 as HF biomarker, not only as a spot prognosticator but also for monitoring the course 
of the disease/congestion status and guiding depletive therapy. Lastly, and along this line, 
given the long half-life of CA125 (7-12 days) (4,5), it can be measured during early 
decompensation without noticing significant changes (17). Conversely, we have found 
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meaningful and significant changes at 30 days and further follow-up, being these changes 
strongly associated with prognosis (4-6). 
 
Limitations 
Some limitations need to be addressed. First, these results do not apply to patients 
with stable chronic HF. Second, the lack of assessment of echocardiographic parameters of 
right ventricular failure and a more detailed evaluation of symptoms and signs of congestion 
precludes evaluating the contribution of these parameters with CA125. Third, we couldn’t 
validate in the external cohort (BIOSTAT-validation cohort) the regression formula obtained 
in the main cohort given the lack of availability of several biomarkers and congestion 
parameters. Instead, a similar statistical approach followed on the main cohort was applied to 
the validation cohort, using the set of covariates available. Fourth, the clinical utility of this 
biomarker in underrepresented AHF phenotypes - such as heart failure with preserved 
ejection fraction, and patients with greater renal dysfunction - remains to be determined. 
Fifth, we cannot evaluate the influence of new treatments, such as sacubitril/valsartan, on the 
magnitude or direction of these findings. Sixth, since this is a predominant cohort of 
Caucasian patients, these findings cannot be extrapolated to other races. Finally, we have not 
compared fresh samples to frozen samples and therefore cannot exclude storage/freeze/thaw 
artifacts.    
 
CONCLUSION 
In patients with signs and/or symptoms of worsening HF, circulating levels of CA125 were 
independently and positively associated with clinical surrogates of congestion. Their levels 
were also highly predictive of 1-year all-cause mortality and of the composite of mortality 
and HF-hospitalization. In addition, such prognostic effect showed to be independent of the 
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severity of systemic congestion. Further studies are warranted to confirm the role of CA125 
as a marker of congestion and unravel the role of this glycoprotein in the pathophysiology of 
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Figure 1. Heatmap and dendrogram 
1a. Biomarker position of CA125 in a correlation heatmap. Correlations are based on 
Spearman’s rho as a correlation coefficient. 
1b. Biomarker position of CA125 in hierarchical cluster analysis.  
Bio-ADM: Bio-adrenomodullin; CA125: antigen carbohydrate 125; CCS: clinical congestion 
score; eGFR: estimated glomerular filtration rate; ET-1; endothelin-1, GDF-15: growth 
differentiation factor-15; IL-6: interleukin-6; NT-proBNP: N-terminal pro-brain natriuretic 
peptide; NYHA: New York Heart Association; SBP: systolic blood pressure. 
N=978 patients. 
 
Figure 2. CCS and NT-proBNP as predictors of logarithm transformed CA125. 
2a. CCS and logarithm transformed CA125. 
2b. NT-proBNP and logarithm transformed CA125. 
Covariates used for adjustment: age (years), systolic blood pressure (mmHg), heart rate 
(bpm), serum sodium (mmol/L), NT-proBNP (pg/mL), hepatomegaly, pulmonary rales, and 
the CCS. 
N=1268, model R2=0.277  
CA125: antigen carbohydrate 125; CCS: clinical congestion score; NT-proBNP: N-terminal 
pro brain natriuretic peptide. 
 
Figure 3: A 1-year multivariable analysis.  




The analysis adjusted by the BIOSTAT risk score for mortality (N=2356). HR depiction 
along the continuum of CA125 (35 U/ml as reference). 
HF: heart failure; HR: hazard ratio; CA125: carbohydrate antigen 125.  
 
Figure 4: A 1-year multivariable analyses including the CCS.  
4a All-cause mortality 
4b. Mortality/HF-readmission 
The analysis adjusted by the 1-y BIOSTAT risk score for the composite endpoint and the 
CCS (N=1426). HR depiction along the continuum of CA125 (35 U/ml as reference).  









The present study confirms the role of CA125 as a surrogate of congestion and its utility as a 
prognostic biomarker in patients with worsening HF. The present data from a sub-analysis of 
the BIOSTAT-CHF and the validation cohorts indicate that CA125 was strongly associated 
with a higher risk of 1-year all-cause mortality and the combined event of all-cause death and 
hospitalization for HF. Moreover, through a cluster analysis, CA125 grouped with recognized 
biomarkers of congestion and inflammation.  
 
TRANSLATIONAL OUTLOOK 
Measurement of CA125 constitutes a valuable tool both for estimating the degree of 
congestion in worsening HF, which can be very useful for clinical management, as well as for 
risk stratification. The fact that it is a biomarker widely available, cheap and with 
standardized measurements, favor its routine use in clinical practice. 
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